Literature DB >> 26866290

Junctional Adhesion Molecule-A Is Highly Expressed on Human Hematopoietic Repopulating Cells and Associates with the Key Hematopoietic Chemokine Receptor CXCR4.

Chao-Hui Chang1,2, Sarah J Hale1,2, Charlotte V Cox3,4, Allison Blair3,4, Barbara Kronsteiner1,2, Rita Grabowska1,2, Youyi Zhang1,2, David Cook1,2, Cheen P Khoo1,2, Jack B Schrader1,2, Suranahi Buglass Kabuga1,2, Enca Martin-Rendon1,2, Suzanne M Watt1,2.   

Abstract

Hematopoietic stem/progenitor cells (HSPCs) reside in specialized bone marrow microenvironmental niches, with vascular elements (endothelial/mesenchymal stromal cells) and CXCR4-CXCL12 interactions playing particularly important roles for HSPC entry, retention, and maintenance. The functional effects of CXCL12 are dependent on its local concentration and rely on complex HSPC-niche interactions. Two Junctional Adhesion Molecule family proteins, Junctional Adhesion Molecule-B (JAM)-B and JAM-C, are reported to mediate HSPC-stromal cell interactions, which in turn regulate CXCL12 production by mesenchymal stromal cells (MSCs). Here, we demonstrate that another JAM family member, JAM-A, is most highly expressed on human hematopoietic stem cells with in vivo repopulating activity (p < .01 for JAM-A(high) compared to JAM-A(Int or Low) cord blood CD34(+) cells). JAM-A blockade, silencing, and overexpression show that JAM-A contributes significantly (p < .05) to the adhesion of human HSPCs to IL-1β activated human bone marrow sinusoidal endothelium. Further studies highlight a novel association of JAM-A with CXCR4, with these molecules moving to the leading edge of the cell upon presentation with CXCL12 (p < .05 compared to no CXCL12). Therefore, we hypothesize that JAM family members differentially regulate CXCR4 function and CXCL12 secretion in the bone marrow niche. Stem Cells 2016;34:1664-1678.
© 2016 AlphaMed Press.

Entities:  

Keywords:  CXCL12; CXCR4; Hematopoietic stem/progenitor cells; JAM-A; NSG transplants; Vascular niche

Mesh:

Substances:

Year:  2016        PMID: 26866290     DOI: 10.1002/stem.2340

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  10 in total

1.  Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast.

Authors:  Mayuri Prasad; Brijesh Kumar; Poornima Bhat-Nakshatri; Manjushree Anjanappa; George Sandusky; Kathy D Miller; Anna Maria Storniolo; Harikrishna Nakshatri
Journal:  Mol Cancer Res       Date:  2019-04-16       Impact factor: 5.852

2.  Development of LT-HSC-Reconstituted Non-Irradiated NBSGW Mice for the Study of Human Hematopoiesis In Vivo.

Authors:  George Adigbli; Peng Hua; Masateru Uchiyama; Irene Roberts; Joanna Hester; Suzanne M Watt; Fadi Issa
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

3.  Skin-resident natural killer T cells participate in cutaneous allergic inflammation in atopic dermatitis.

Authors:  ZhengWang Sun; Ji Hye Kim; Seo Hyeong Kim; Hye Ran Kim; KeLun Zhang; Youdong Pan; Min Kyung Ko; Bo Mi Kim; Howard Chu; Hee Ra Lee; Hye Li Kim; Ji Hyung Kim; Xiujun Fu; Young-Min Hyun; Ki Na Yun; Jin Young Kim; Dong Won Lee; Seung Yong Song; Charles P Lin; Rachael A Clark; Kwang Hoon Lee; Thomas S Kupper; Chang Ook Park
Journal:  J Allergy Clin Immunol       Date:  2021-01-28       Impact factor: 14.290

4.  JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.

Authors:  Peng-Peng Xu; Yi-Feng Sun; Ying Fang; Qi Song; Zi-Xun Yan; Yi Chen; Xu-Feng Jiang; Xiao-Chun Fei; Yan Zhao; Christophe Leboeuf; Biao Li; Chao-Fu Wang; Anne Janin; Li Wang; Wei-Li Zhao
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

5.  JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.

Authors:  A G Solimando; A Brandl; K Mattenheimer; C Graf; M Ritz; A Ruckdeschel; T Stühmer; Z Mokhtari; M Rudelius; J Dotterweich; M Bittrich; V Desantis; R Ebert; P Trerotoli; M A Frassanito; A Rosenwald; A Vacca; H Einsele; F Jakob; A Beilhack
Journal:  Leukemia       Date:  2017-09-28       Impact factor: 11.528

6.  Single-cell assessment of transcriptome alterations induced by Scriptaid in early differentiated human haematopoietic progenitors during ex vivo expansion.

Authors:  Peng Hua; Barbara Kronsteiner; Mark van der Garde; Neil Ashley; Diana Hernandez; Marina Tarunina; Lilian Hook; Yen Choo; Irene Roberts; Adam Mead; Suzanne M Watt
Journal:  Sci Rep       Date:  2019-03-28       Impact factor: 4.379

7.  A Novel High-Throughput Screening Platform Reveals an Optimized Cytokine Formulation for Human Hematopoietic Progenitor Cell Expansion.

Authors:  Marina Tarunina; Diana Hernandez; Barbara Kronsteiner-Dobramysl; Philip Pratt; Thomas Watson; Peng Hua; Francesca Gullo; Mark van der Garde; Youyi Zhang; Lilian Hook; Yen Choo; Suzanne M Watt
Journal:  Stem Cells Dev       Date:  2016-09-30       Impact factor: 3.272

8.  Protein profiling identified key chemokines that regulate the maintenance of human pluripotent stem cells.

Authors:  Zongmin Jiang; Yonggang Li; Xinglai Ji; Yiyuli Tang; Haijing Yu; Lei Ding; Min Yu; Qinghua Cui; Ming Zhang; Yanping Ma; Meizhang Li
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

9.  JAM-C/Jam-C Expression Is Primarily Expressed in Mouse Hematopoietic Stem Cells.

Authors:  Elia Henry; Vilma Barroca; Cécile K Lopez; Michel Aurrand-Lions; Daniel Lewandowski; Thomas Mercher; Marie-Laure Arcangeli
Journal:  Hemasphere       Date:  2021-06-12

10.  Hematopoietic progenitors polarize in contact with bone marrow stromal cells in response to SDF1.

Authors:  Thomas Bessy; Adrian Candelas; Benoit Souquet; Khansa Saadallah; Alexandre Schaeffer; Benoit Vianay; Damien Cuvelier; Samy Gobaa; Cecilia Nakid-Cordero; Julien Lion; Jean-Christophe Bories; Nuala Mooney; Thierry Jaffredo; Jerome Larghero; Laurent Blanchoin; Lionel Faivre; Stephane Brunet; Manuel Théry
Journal:  J Cell Biol       Date:  2021-09-27       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.